Total Payments
$136,380
2024 Payments
$65,421
Companies
53
Transactions
710
Medicare Patients
7,424
Medicare Billing
$708,977
Payment Breakdown by Category
Other$113,172 (83.0%)
Food & Beverage$17,083 (12.5%)
Travel$5,676 (4.2%)
Education$448.40 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113,172 | 46 | 83.0% |
| Food and Beverage | $17,083 | 642 | 12.5% |
| Travel and Lodging | $5,676 | 15 | 4.2% |
| Education | $448.40 | 7 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $46,456 | 100 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $34,224 | 90 | $0 (2024) |
| Novo Nordisk Inc | $27,524 | 29 | $0 (2024) |
| Esperion Therapeutics, Inc. | $17,150 | 20 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,904 | 71 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $1,196 | 17 | $0 (2024) |
| Amgen Inc. | $1,024 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $982.42 | 71 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $906.78 | 26 | $0 (2020) |
| PFIZER INC. | $771.05 | 54 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,421 | 135 | Novo Nordisk Inc ($27,144) |
| 2023 | $10,523 | 85 | Boston Scientific Corporation ($5,538) |
| 2022 | $9,573 | 52 | Boston Scientific Corporation ($8,539) |
| 2021 | $32,234 | 82 | Esperion Therapeutics, Inc. ($17,084) |
| 2020 | $11,456 | 68 | Boston Scientific Corporation ($6,227) |
| 2019 | $3,415 | 106 | Boston Scientific Corporation ($1,181) |
| 2018 | $2,080 | 90 | Janssen Pharmaceuticals, Inc ($578.95) |
| 2017 | $1,677 | 92 | Astellas Pharma US Inc ($214.71) |
All Payment Transactions
710 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ENDOTRONIX, INC. | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR (Device) | Food and Beverage | Cash or cash equivalent | $6.40 | General |
| Category: HEART FAILURE | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $2.05 | General |
| Category: Cardiovascular | ||||||
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.13 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $99.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $73.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/16/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $200.33 | General |
| Category: Cardiovascular Diseases | ||||||
| 11/16/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $6.85 | General |
| Category: Cardiovascular Diseases | ||||||
| 11/14/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/12/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,943.75 | General |
| 10/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,137.33 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,146 | 2,795 | $599,740 | $208,410 |
| 2022 | 21 | 1,972 | 2,632 | $569,614 | $183,492 |
| 2021 | 21 | 1,751 | 2,311 | $493,240 | $175,644 |
| 2020 | 21 | 1,555 | 2,048 | $405,192 | $141,431 |
Total Patients
7,424
Total Services
9,786
Medicare Billing
$708,977
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 437 | 624 | $171,600 | $57,627 | 33.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 295 | 547 | $117,605 | $52,724 | 44.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 151 | 151 | $67,830 | $23,270 | 34.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 123 | 126 | $52,290 | $17,917 | 34.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 62 | 62 | $31,310 | $9,405 | 30.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 133 | 135 | $19,575 | $7,192 | 36.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 95 | 110 | $16,500 | $7,027 | 42.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 441 | 609 | $33,495 | $6,580 | 19.6% |
| 93931 | Ultrasound of one arm arteries or artery grafts | Office | 2023 | 75 | 75 | $24,500 | $6,159 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $11,520 | $4,243 | 36.8% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 29 | 30 | $13,680 | $4,224 | 30.9% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 22 | 22 | $9,240 | $3,323 | 36.0% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 15 | 15 | $8,175 | $2,888 | 35.3% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 19 | 19 | $5,415 | $1,679 | 31.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 14 | 22 | $3,960 | $1,357 | 34.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $3,990 | $1,233 | 30.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 128 | 140 | $5,560 | $843.28 | 15.2% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 13 | 14 | $770.00 | $281.96 | 36.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 13 | $715.00 | $232.68 | 32.5% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 12 | 12 | $1,260 | $108.96 | 8.6% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 12 | 12 | $420.00 | $69.72 | 16.6% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 11 | 11 | $330.00 | $27.17 | 8.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 387 | 576 | $170,190 | $53,930 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 248 | 490 | $109,860 | $40,393 | 36.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 133 | 134 | $60,515 | $21,201 | 35.0% |
About Dr. Rakesh Shah, M.D
Dr. Rakesh Shah, M.D is a Cardiovascular Disease healthcare provider based in Langhorne, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144297219.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Shah, M.D has received a total of $136,380 in payments from pharmaceutical and medical device companies, with $65,421 received in 2024. These payments were reported across 710 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($113,172).
As a Medicare-enrolled provider, Shah has provided services to 7,424 Medicare beneficiaries, totaling 9,786 services with total Medicare billing of $708,977. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Langhorne, PA
- Active Since 03/07/2006
- Last Updated 05/26/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1144297219
Products in Payments
- WATCHMAN Access System (Device) $29,080
- LOKELMA (Drug) $18,409
- Ozempic (Drug) $17,999
- WATCHMAN (Device) $16,643
- FARXIGA (Drug) $15,255
- NEXLIZET (Drug) $10,266
- NEXLETOL (Drug) $6,884
- XARELTO (Drug) $1,904
- Optimizer (Device) $920.23
- ENTRESTO (Drug) $736.15
- WATCHMAN FLX (Device) $666.21
- ELIQUIS (Drug) $590.10
- MULTAQ (Drug) $566.16
- Corlanor (Drug) $497.84
- Repatha (Biological) $401.27
- BRILINTA (Drug) $382.71
- PRALUENT (Drug) $340.62
- OPTIMIZER (Device) $276.13
- Impella (Device) $251.41
- VERQUVO (Drug) $250.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Langhorne
Frank Ammaturo, M.d, M.D
Cardiovascular Disease — Payments: $25,869
Cardiovascular Disease $25,869
Anand Haridas, M.d, M.D
Cardiovascular Disease — Payments: $18,256
Cardiovascular Disease $18,256
Andrew Friedman, Do, DO
Cardiovascular Disease — Payments: $9,374
Cardiovascular Disease $9,374
Eyad Kanawati, M.d, M.D
Cardiovascular Disease — Payments: $8,981
Cardiovascular Disease $8,981
Dr. Ranga Rao, Md, MD
Cardiovascular Disease — Payments: $8,305
Cardiovascular Disease $8,305
Srinivas Atri, Md, MD
Cardiovascular Disease — Payments: $8,158
Cardiovascular Disease $8,158